复方阿胶浆治疗贫血的安全性观察

Evaluation of the Clinical Safety of Fufang Ejiao Jiang in Treating Anemia

目的:评价复方阿胶浆治疗贫血的临床安全性。方法:收集2010年1月至2011年12月期间收治的贫血患者口服复方阿胶浆1 200例,观察治疗1个月后所有患者的不良反应及白细胞分类、肝、肾功能的变化,并对所有服药患者的不良反应发生率进行安全性监测,评价复方阿胶浆的安全性。结果:1 200例服用复方阿胶浆的患者的不良反应发生率为0.83%,以消化系统反应的发生率最高,其他不良反应如头晕、恶心、呕吐、过敏反应发生率低,不良事件的持续时间短,全部好转或消失;实验室检查白细胞及分类、转氨酶、尿素氮变化不大,没有统计学意义。结论:复方阿胶浆治疗贫血具有良好的临床安全性。

Objective： To evaluate the clinical safety of Fufang Ejiao Jiang in treatment of anemia. Method： In 2010 January-2011 December, 1 200 cases of anemia were treated with Fufang Ejiao Jiang. After 1 months of treatment, evaluate the adverse drug reaction and the changes of classification of blood white blood cells, and the function of liver and kidney, and monitor the incidence of adverse reactions. Result： The incidence of adverse reaction rate was 0.83% on the 1 200 cases of anemia, the highest incidence was digestive system reaction, other adverse reactions rate was lower, such as Dizziness, nausea, vomiting, allergic reaction, and lasted for a short duration, all disappeared or improved. The changes of classification of leukocytes, transaminase, blood urea nitrogen, was little and no significant difference. Conclution： Fufang Ejiao Jiang is safe for treating anemia in clinical use.